Drug Trial Radar · NCT03814291
A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Apr 15, 2019
Primary completion
Mar 5, 2020
Study completion Apr 10, 2020
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
IBI302Drug
0.05mg/eye;Intraocular injection
IBI302Drug
0.15mg/eye;Intraocular injection
IBI302Drug
0.5mg/eye;Intraocular injection
IBI302Drug
1mg/eye;Intraocular injection
IBI302Drug
2mg/eye;Intraocular injection
IBI302Drug
4mg/eye;Intraocular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluation indicatorsTime frame: Baseline to Day43
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.